Compugen Ltd. (NASDAQ:CGEN) Receives Consensus Recommendation of "Buy" from Brokerages

Key Points

• Compugen has a consensus “Buy” rating from five brokerages: three buys, one strong buy and one hold. The average 12-month price target is $5.00.
• Compugen reported a quarterly loss of $0.07 per share, beating estimates of a $0.08 loss, while revenue of $2.60 million exceeded the $1.28 million consensus forecast.
• Institutional ownership stands at 12.22%, with hedge funds including Jane Street Group and Renaissance Technologies recently increasing their positions.

Compugen Ltd. (NASDAQ:CGEN - Get Free Report) has earned a consensus rating of "Buy" from the five brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $5.00.

Several equities research analysts recently commented on CGEN shares. Wall Street Zen downgraded shares of Compugen from a "buy" rating to a "hold" rating in a research report on Saturday, May 23rd. HC Wainwright reiterated a "buy" rating on shares of Compugen in a research report on Tuesday, August 4th. Weiss Ratings raised shares of Compugen from a "sell (d-)" rating to a "hold (c-)" rating in a research note on Wednesday, August 5th. Finally, Leerink Partners reduced their target price on Compugen from $13.00 to $5.00 and set an "outperform" rating for the company in a report on Thursday, May 21st.

Compugen Trading Down 5.8%

NASDAQ CGEN opened at $2.60 on Friday. The stock's 50-day moving average price is $2.36 and its two-hundred day moving average price is $2.33. The company has a market cap of $245.83 million, a PE ratio of 6.84 and a beta of 2.77. Compugen has a 1 year low of $1.29 and a 1 year high of $3.23.

Compugen (NASDAQ:CGEN - Get Free Report) last announced its earnings results on Monday, August 3rd. The biotechnology company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. The company had revenue of $2.60 million during the quarter, compared to analysts' expectations of $1.28 million. Compugen had a net margin of 47.56% and a return on equity of 42.57%. During the same period last year, the company posted ($0.08) earnings per share. Research analysts forecast that Compugen will post -0.27 EPS for the current fiscal year.

Institutional Investors Weigh In On Compugen

Hedge funds have recently bought and sold shares of the business. Jane Street Group LLC boosted its position in Compugen by 1,077.0% during the 2nd quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company's stock worth $700,000 after acquiring an additional 359,785 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Compugen by 12.1% in the 1st quarter. Renaissance Technologies LLC now owns 1,632,988 shares of the biotechnology company's stock valued at $3,478,000 after purchasing an additional 176,088 shares during the period. XTX Topco Ltd acquired a new position in shares of Compugen in the 4th quarter valued at about $104,000. Marshall Wace LLP increased its holdings in shares of Compugen by 135.7% in the 4th quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company's stock valued at $163,000 after purchasing an additional 61,202 shares during the period. Finally, WINTON GROUP Ltd purchased a new stake in shares of Compugen in the fourth quarter worth approximately $84,000. 12.22% of the stock is owned by hedge funds and other institutional investors.

About Compugen

Compugen Ltd. NASDAQ: CGEN is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen's predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.